Table 2.
Carnitine palmitoyltransferase-1a expression according to IHC score.
| Carnitine Palmitoyltransferase-1a | p-Value | ||
|---|---|---|---|
| Low-IRS (n = 325) | High-IRS (n = 65) | ||
| Age (years), median (IQR) | 70.0 (64.0–74.0) | 68.0 (64.0–74.0) | <0.01 |
| PSA (ng/mL), median IQR) | 6.43 (4.05–10.0) | 7.0 (4.9–10.01) | <0.01 |
| Fasting glucose (mg/dL), median (IQR) | 96.0 (88.0–109) | 99.0 (87.0–111.0) | 0.71 |
| Total cholesterol (mg/dL), median (IQR) | 187.0 (158.0–214.0) | 179.0 (152.0–200.0) | <0.01 |
| Triglycerides (mg/dL), median (IQR) | 99.0 (68.0–137.0) | 121.0 (73.0–170.0) | <0.01 |
| Diabetes, n (%) | 61 (18.77) | 11 (16.92) | 0.73 |
| Group, n (%) | 0.02 | ||
| BPH | 94 (28.92) | 10 (15.38) | |
| PC | 231 (71.08) | 55 (84.62) | |
| ISUP Gleason score, n (%) | 0.84 | ||
| 1 | 68 (29.44) | 14 (25.45) | |
| 2 | 89 (38.53) | 21 (38.18) | |
| 3 | 52 (22.51) | 14 (25.45) | |
| 4 | 12 (5.19) | 2 (3.64) | |
| 5 | 10 (4.33) | 4 (7.27) | |
| Pathological stage, n (%) | 0.95 | ||
| T2 | 159 (69.13) | 37 (67.27) | |
| T3 | 42 (18.26) | 11 (20.0) | |
| T4 | 29 (12.61 | 7 (12.73) | |
| Classification risk of PC, n (%) | 0.14 | ||
| Low risk | 87 (37.6) | 13 (23.64) | |
| Intermediate risk | 98 (42.42) | 28 (50.91) | |
| High risk | 46 (19.91) | 14 (25.45) | |
| Ki-67 positive score, n (%) | 53 (15.73) | 12 (22.64) | 0.21 |
| AR positive score, n (%) | 25 (12.02) | 40 (21.98) | <0.01 |
| PSMA positive score, n (%) | 36 (14.88) | 29 (19.59) | 0.22 |
| IR-α positive score, n (%) | 10 (7.63) | 55 (21.24) | <0.01 |
| IR-β positive score, n (%) | 57 (15.53) | 8 (34.78) | 0.02 |
| IGF-1R positive score, n (%) | 53 (16.26) | 12 (18.75) | 0.62 |
| SRSF-1 positive score, n (%) | 23 (11.39) | 42 (22.34) | <0.01 |
| ATP-citrate lyase positive score, n (%) | 30 (14.78) | 35 (18.72) | 0.29 |
| SCD-1 positive score, n (%) | 49 (15.08) | 16 (24.62) | 0.06 |
| SREBP1 positive score, n (%) | 41 (13.95) | 24 (25.00) | 0.01 |
| FAS positive score, n (%) | 15 (8.43) | 50 (23.58) | <0.01 |
| ACC-1 positive score, n (%) | 29 (11.79) | 36 (25.00) | <0.01 |
IRS = immunoreactivity score BPH= Benign Prostatic Hyperplasia; PCa = prostate cancer; IQR = interquartile range; AR = Androgenic receptor; IR = insulin receptor; IGF-1R = insulin-like growth factor-1 receptor; PSMA = prostate specific membrane antigen; SRSF-1 = Serine/arginine-rich splicing factor 1; FAS = fatty acid synthase; CPT-1a = Carnitine palmitoyltransferase 1a; SCD-1 = Stearoyl-CoA desaturase-1; SREBP-1 = Sterol regulatory element-binding protein-1; AC-1 = Acetyl-CoA Carboxylase-1.